Noxafil

NDA 22027, held by Schering. Posaconazole.

As of Nov 14, 2026, NDA 22027 (Noxafil), held by Schering, was first approved by FDA on Oct 20, 2006, with 3 approved supplements and 0 published complete response letters.

• First approved: Oct 20, 2006
• Supplements approved: 3
• Complete response letters: 0

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters